Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–380 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Paracentesis Clear all
Recruiting Phase 2 Interventional

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
146
States / cities
Berkeley, California • Irvine, California • Orange, California + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 8:59 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
View directory record Official record
Conditions
Elective Cesarean Section, Pain Management
Interventions
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 23, 2026, 8:59 AM EDT
Recruiting Phase 2 Interventional

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

NCT05998135
View directory record Official record
Conditions
Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Interventions
Atovaquone, Biopsy, Computed Tomography, Paracentesis
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

NCT00932152
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Postmenopausal Women
Interventions
fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

NCT04539041
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
antisense oligonucleotide, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Unilateral TAP Block for Laparoscopic Gastric Sleeve Surgery

NCT03856788
View directory record Official record
Conditions
Laparoscopic Sleeve Gastrectomy, Subcostal Transversus Abdominis Plane Block
Interventions
Saline, Bupivacaine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 23, 2026, 8:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

NCT02696603
View directory record Official record
Conditions
Parkinson Disease, Neurodegenerative Diseases, Movement Disorders, Central Nervous System Diseases, Brain Diseases, Basal Ganglia Diseases, Parkinsonian Disorders
Interventions
Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, Participant open-response writing, Parkinson mPower mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy

NCT02519023
View directory record Official record
Conditions
Acute Pain
Interventions
Liposomal Bupivacaine, Bupivacaine, Ultrasound, Epinephrine, acetaminophen, ibuprofen, Oxycodone
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 23, 2026, 8:59 AM EDT
Recruiting Phase 2 Interventional

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

NCT06895473
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Biospecimen Collection, Cytarabine, Lumbar Puncture, Methotrexate, Therapeutic Hydrocortisone
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 8:59 AM EDT
Suspended Phase 1 Interventional

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

NCT06922604
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Glofitamab, Lumbar Puncture, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 8:59 AM EDT
Terminated Not applicable Interventional Results available

Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy

NCT02164929
View directory record Official record
Conditions
Laparoscopic Colorectal Resection
Interventions
TAP block, Epidural, Paravertebral block, Acetaminophen 1g IV, Dexamethasone 4mg, Midazolam up to 2mg, Propofol 1-2.5 mg/kg, Sevoflurane to keep a bispectral index of between 40-60, Local infiltration with 10 mL of plain ropivacaine 0.25%, Lidocaine, Epinephrine, Hydromorphone
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brief Online Help-seeking Barrier Reduction Intervention

NCT03633825
View directory record Official record
Conditions
Crisis Intervention, Suicide and Depression
Interventions
Brief help-seeking barrier reduction intervention
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
Not listed
Enrollment
39,450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses

NCT02662023
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bolus, Basal
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 23, 2026, 8:59 AM EDT
Not yet recruiting Not applicable Interventional

Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis

NCT07755059
View directory record Official record
Conditions
Ascites, Liver Cirrhosis, Hypertension, Portal
Interventions
Proximal Splenic Artery Embolization
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 8:59 AM EDT
Recruiting Phase 1 Interventional

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT06871410
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine Phosphate, Hydroxyurea, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 8:59 AM EDT
Recruiting Early Phase 1 Interventional

Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.

NCT06617949
View directory record Official record
Conditions
Substance Use Disorder (SUD)
Interventions
Regional Anesthesia, Hydromorphone Patient Controlled Analgelsic, Epidural local anesthetic infusion
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 23, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Study in Subjects Undergoing Complete Abdominoplasty

NCT03789318
View directory record Official record
Conditions
Postsurgical Pain
Interventions
CA-008 5 mg, Placebo, Bupivacaine Hydrochloride, Hydromorphone, Fentanyl, Acetaminophen, Oxycodone, CA-008 10 mg, CA-008 15 mg
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 8:59 AM EDT
Recruiting Not applicable Interventional

Transcranial Alternating Current Stimulation (tACS) for the Treatment of Anxiety in Veterans: An Open-Label Pilot Study

NCT07288008
View directory record Official record
Conditions
Anxiety
Interventions
Transcranial alternating current stimulator
Device
Lead sponsor
Birmingham VA Health Care System
Federal
Eligibility
19 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 8:59 AM EDT
Terminated Not applicable Interventional

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

NCT02441140
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Culdocentesis, Vaginal Swab, Chromopertubation, Blood collection, Tissue collection
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 23, 2026, 8:59 AM EDT